Difficulties in diagnosis and treatment of severe secondary Raynaud’s phenomenon in a Cameroonian woman: a case report

Valérie Ndip Agbor 1*, Tsi Njim 2 and Leopold Ndemnge Aminde 3,4

Abstract

Background: Raynaud’s phenomenon is a microvascular disorder that results in exaggerated vasoconstriction over vasodilatation secondary to an alteration in autonomic control. Though benign, it can result in severe ulceration and ultimately gangrene associated with disfiguration and permanent deformity. We present a case of severe secondary Raynaud’s phenomenon in a black-African patient from a resource-limited setting, with focus on the difficulties encountered in the diagnosis and treatment.

Case presentation: A 43-year-old female Cameroonian farmer with a 7-year history of episodic paresthesia in her fingers and toes (when exposed to cold) presented to our emergency department with severe pain, ulceration, and “darkening” of her fingertips over a period of 2 days. An examination revealed bilateral ulceration and dry gangrene of her fingers and toes, based on which a diagnosis of secondary Raynaud’s phenomenon due to a connective tissue disease was proposed. Results of paraclinical investigations were normal. Lifestyle modification along with a calcium channel blocker and phosphodiesterase type 5 inhibitor provided significant relief.

Conclusions: An early diagnosis and knowledge on appropriate treatment of Raynaud’s phenomenon is of vital importance to prevent permanent tissue damage and disability. Relying on biphasic color change for the diagnosis of Raynaud’s phenomenon in black Africans can be potentially misleading.

Keywords: Secondary Raynaud’s phenomenon, Connective tissue disease, Cameroon
were observed. The rest of the physical examination was not contributory. A presumptive diagnosis of severe secondary RP due to a connective tissue disease was made. Her erythrocyte sedimentation rate (ESR), fasting blood sugar, anti-streptolysin O antigen (ASLO) level, human immunodeficiency virus (HIV) serology, urine analysis, and rheumatoid factor concentration were all negative. A Doppler ultrasonography of her peripheral blood vessels was normal. Blood samples for anti-nuclear antibodies (ANA) and anti-topoisomerase (anti-Scl 70) antibodies were collected and preserved to be sent abroad for analysis, though plans fell through due to financial constraints.

---

Fig. 1 Dorsal and palmar view of ulceration and gangrene of the distal third of the right index finger (left), and the distal third fingers of the left hand (right)

Fig. 2 Symmetric affection with ulceration and gangrene of the toes
We admitted her to our intensive care unit. Non-pharmacological treatment included stopping diclofenac (and other prostaglandin inhibitors); putting on warm clothing; placing her hands and feet in lukewarm water; and avoiding consumption of caffeine-containing products, cold exposure, and smoking (active or passive). Pharmacological measures included nifedipine, 20 mg per os thrice daily; sildenafil, 15 mg per os thrice daily; cloxacillin, 500 mg thrice daily; tramadol, 100 mg start dose given intravenously; and open dressing of her ulcers. Complete analgesia was achieved within 45 minutes and, after 3 days of inpatient management, our patient was stable and referred to a rheumatologist for further management but was lost to follow-up.

Discussion
Globally, primary RP is fairly common with a prevalence of 3–5% predominantly in cold climates [1]. The prevalence of secondary RP depends on the associated disease, reaching up to 90% in patients with systemic sclerosis [3]. No epidemiologic data on this phenomenon is available in Africa.

The following have been suggested as driving factors in RP: cold (most common), emotional stress, drugs such as beta blockers, prolonged use of digits (like prolonged typing and piano playing), smoking, and the presence of an underlying vascular disease [1]. Cold and farming (associated with prolonged use of digits) were most likely the trigger factors of our patient’s crisis, with possible aggravation by diclofenac, which inhibits prostaglandin synthesis by inhibiting cyclo-oxygenase.

RP results from an exaggeration of vasoconstriction of the pre-arteriolar capillaries over vasodilatation, secondary to an alteration in the neurological control of the vasomotor tone and circulating mediators [4]. The autonomic nervous system overreacts and overproduces endothelin 1 (a potent vasoconstrictor also associated with vascular fibrosis) with respect to prostaglandin E2 [PG E2 (a vasodilator)], leading to excessive vasoconstriction [5]. This results in the episodic and symmetrical triphasic color change (pallor, cyanosis, and rubor), trophic skin changes, and uncomfortable sensory symptoms in the involved extremities (paresthesia in our case) [6]. On exposure to cold, the distal finger pads initially become pale as a result of vasoconstriction, then cyanosis occurs, secondary to tissue hypoxia, and finally they turn red, as tissue reperfusion occurs [1]. RP has been classified clinically into two types: primary RP, which is mostly benign; and secondary RP, which in 10–20% of cases is associated with an underlying systemic disease [such as Sjögren’s syndrome, systemic sclerosis, CREST syndrome (calcinosis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia), systemic lupus erythematosus, or dermatomyositis], or with drugs or extrinsic vascular obstruction [7]. Primary RP is characterized by symmetrical attacks on the digits in the absence of peripheral vascular disease, tissues necrosis, ulceration, or gangrene [2, 8]. Meanwhile, the attacks of secondary RP are associated with more severe asymmetric affection with tissue necrosis, ulceration, and gangrene [2, 8]. Scleroderma syndrome, which can present as CREST syndrome (also called limited systemic sclerosis) and systemic sclerosis (also called diffuse systemic sclerosis) have been associated with severe secondary RP [8]. Our patient, however, had no features suggestive of CREST syndrome. The presence of digital tissue ulceration and gangrene associated with a history of arthralgia in our patient supports the diagnosis of secondary RP due to a systemic disease, but owing to some adversities we could not establish a precise etiology.

The diagnosis of RP in people of black ethnicity can be challenging. Among others, an important hallmark for the diagnosis of RP is the presence of a biphasic color change [1]. This feature is difficult to appreciate in the absence of an attack and in a dark-skinned patient like the index case. Indeed, our patient only presented with pallor of the affected fingers. This raises a potential limitation of this feature as a major diagnostic criterion for RP in black Africans. Although capillaroscopy has a high positive predictive value in detecting the likelihood of a patient having or developing a connective tissue disease [9], this could not be performed due to the limitations of our health facility. In addition, a normal ESR and ASLO and rheumatoid factor concentrations were not indicative of a systemic disease. Furthermore, an analysis of ANA and anti-Scl 70 antibodies could not be done owing to financial constraints and the limited availability of these tests in Cameroon at the time.

There is currently no cure nor gold standard therapy for RP [10] even though many advances have been made as far as pharmacological treatment is concerned [3]. The management of RP depends on whether it is primary or secondary, and it generally involves non-pharmacological and pharmacological measures. Non-pharmacological treatment entails lifestyle modifications such as avoiding cold temperatures, emotional stress, caffeine, smoking, and vasoconstrictive drugs [3]. Lifestyle modification may potentially suffice for the management of primary RP. In cases where lifestyle modification is inadequate, calcium channel blockers (CCBs) or topical nitrates can be added [3].

In secondary RP, pharmacological treatment usually accompanies lifestyle modifications. Iloprost (a prostaglandin analog), sildenafil (a phosphodiesterase type 5 inhibitor), topical nitrates (vasodilators), and bosentan (an endothelin receptor antagonist) could be added to CCBs for patients who experience persistent intense pain, ulceration, and gangrene [3]. Iloprost and sildenafil can reduce the frequency, duration, and severity of
attacks, and also improve ulcer healing. Bosentan reduces the incidence of new digital ulcers [3]. In patients with persistent severe ischemia, a surgical consultation for digital sympathectomy is recommended [8]. With lifestyle modification and treatment with nifedipine and sildenafil, signs of ischemia were halted in our patient. Iloprost was not administered, because it was unavailable in local pharmacies.

Unfortunately, our patient presented for treatment with the ultimate complication of her crisis, gangrene, affecting several digits. The only treatment available for gangrene is amputation, resulting in permanent disability.

Conclusions
We have presented a case of severe secondary RP in a black African woman from a resource-limited setting. Early diagnosis of this condition and appropriate management is pivotal to prevent tissue necrosis and amputation of the affected digits in extreme cases. The classical biphasic color change during crisis should not be solely relied on to make the diagnosis of RP in black Africans.

Abbreviations
ANA: Anti-nuclear antibodies; ASLO: Anti-streptolysin O antigen; CCBs: Calcium channel blockers; CREST: Calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; ESR: Erythrocyte sedimentation rate; PG E2: Prostaglandin E2; RP: Raynaud's phenomenon

Acknowledgements
Not applicable.

Funding
None.

Availability of data and materials
The dataset and images supporting the conclusions of this case report are included within the article.

Authors’ contributions
VN assisted in patient management, did the literature search, and wrote the case report. LNA and TN critically revised the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of the case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
Not applicable.

Author details
1Ibal Sub-Divisional Hospital, Oku, North West Region, Cameroon. 2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxfordshire, UK. 3Clinical Research Education, Networking and Consultancy (CREN), Douala, Littoral, Cameroon. 4School of Public Health, Faculty of Medicine & Biomedical Sciences, University of Queensland, Brisbane, Australia.

Received: 3 October 2016 Accepted: 9 November 2016
Published online: 20 December 2016

References
1. Maverakis E, Patel F, Kronenberg D, Chung L, Fiorentino D, Allanore Y, et al. International Consensus Criteria for the Diagnosis of Raynaud's Phenomenon. J Autoimmun. 2014;68:5–9.
2. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med. 2002; 347:1001–8.
3. Levien TL. Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag. 2010;6:167–77.
4. Baumhökel M, Böhm M. Recent achievements in the management of Raynaud's phenomenon. Vasc Health Risk Manag. 2010;6:207–14.
5. Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R, et al. Increased asymmetric dimethylarginine and endothelin-1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. 2003;48:1992–2000.
6. Garner R, Kumar R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5:e006389.
7. Lee R, Lomas O, Handa A. Severe Raynaud's phenomenon—a streamlined approach to acute management. Int J Surg Case Rep. 2011;2:61–2.
8. McMahan ZH, Wigley FM. Raynaud’s phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management. Int J Clin Rheumatol. 2010;5:355–70.
9. Lambova SN, Müller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int. 2009;29:1263–71.
10. Bakst R, Merola JF, Franks AG, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59:633–53.